Oprelvekin Articles
Weak core products sales at Yamanouchi
31 May 2004
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
American Home Pharma Sales Up 7% For 2nd Qtr
22 July 1998
AHP Looks To Bright Future With New Products
30 April 1998
New Products In 1998; A Look Ahead
6 January 1998
First Approval For Genetics Institute's Neumega
4 December 1997
Genetics Institute: Neumega Approved By FDA
27 November 1997
Genetics Institute's Neumega Backed By FDA Panel
30 July 1997
FDA To Fast-Track Genetics Institute's Neumega
24 July 1997
Schering-Plough Chief Gives R&D Update
10 June 1996
1995 A Turning Point For Genetics Institute
6 May 1996
What Future For Biotechnology At AHP?
15 April 1996
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
GENETICS INSTITUTE PREVIEWS IL-11 DATA
25 October 1993
GENETICS INSTITUTE SEEING R&D RETURNS
5 April 1993
Showing 1-21 of 21 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
